You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dextrose 5% In Lactated Ringer's In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed University of Washington N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗ Hypertonic Saline Use in Preeclampsia Completed Johns Hopkins University Phase 1 2003-06-01 To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dextrose 5% In Lactated Ringer's In Plastic Container

Condition Name

Condition Name for Dextrose 5% In Lactated Ringer's In Plastic Container
Intervention Trials
Anesthesia 5
Post-ERCP Acute Pancreatitis 4
Cesarean Section 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dextrose 5% In Lactated Ringer's In Plastic Container
Intervention Trials
Hypotension 16
Pancreatitis 11
Hemorrhage 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dextrose 5% In Lactated Ringer's In Plastic Container

Trials by Country

Trials by Country for Dextrose 5% In Lactated Ringer's In Plastic Container
Location Trials
Egypt 37
United States 33
China 12
Korea, Republic of 5
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dextrose 5% In Lactated Ringer's In Plastic Container
Location Trials
Illinois 4
Pennsylvania 3
Connecticut 3
California 3
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dextrose 5% In Lactated Ringer's In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Dextrose 5% In Lactated Ringer's In Plastic Container
Clinical Trial Phase Trials
Phase 4 39
Phase 3 14
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dextrose 5% In Lactated Ringer's In Plastic Container
Clinical Trial Phase Trials
Completed 64
Not yet recruiting 29
Recruiting 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dextrose 5% In Lactated Ringer's In Plastic Container

Sponsor Name

Sponsor Name for Dextrose 5% In Lactated Ringer's In Plastic Container
Sponsor Trials
Ain Shams University 9
Cairo University 6
Mansoura University 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dextrose 5% In Lactated Ringer's In Plastic Container
Sponsor Trials
Other 214
Industry 17
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER: Clinical Trials, Market Analysis, and Projections

Introduction

Dextrose 5% in Lactated Ringer's Solution (D5LRS) is a widely used intravenous fluid that provides essential electrolytes, calories, and hydration. This solution is crucial in various clinical settings, including fluid replacement, electrolyte balance, and nutritional support. Here, we will delve into recent clinical trials, market analysis, and future projections for D5LRS.

Clinical Uses and Composition

D5LRS is a hypertonic, nonpyrogenic parenteral fluid that contains dextrose, sodium chloride, sodium lactate, potassium chloride, and calcium chloride. Each 100 mL of the solution includes 5 g of dextrose, 0.6 g of sodium chloride, 0.31 g of sodium lactate, 0.03 g of potassium chloride, and 0.02 g of calcium chloride dihydrate[2].

Mechanism of Action

The solution works by increasing intravascular osmotic pressure, pulling fluid into the vascular space through osmosis, and providing necessary electrolytes and calories. The lactate in the solution helps in producing a metabolic alkalinizing effect, which is beneficial in maintaining acid-base balance[1].

Clinical Trials

Recent Studies

A recent randomized controlled trial compared the effects of 5% Dextrose in Lactated Ringer's (RLD5) versus 5% Dextrose in Normal Saline (DNS) in non-critically ill children. The study aimed to estimate differences in serum chloride levels, incidence of dyselectrolytemia, hyperchloremic metabolic acidosis (HCMA), acute kidney injury (AKI), and all-cause mortality. The results showed a statistically significant difference in serum chloride levels between the two groups, with lower incidence of HCMA in the RLD5 group. There was no mortality in either group[4].

Key Findings

  • Serum Chloride Levels: The study found a significant difference in serum chloride levels between RLD5 and DNS groups.
  • Hyperchloremic Metabolic Acidosis: The incidence of HCMA was lower in the RLD5 group compared to the DNS group.
  • Acute Kidney Injury: The incidence of AKI was slightly higher in the RLD5 group but was not clinically significant.
  • Mortality: There was no mortality reported in either group.

Market Analysis

Market Size and Growth

The global lactated Ringer's injection market, which includes D5LRS, is projected to grow significantly. As of 2024, the market is valued at USD 510.1 million and is expected to reach USD 762.2 million by 2031, with a compound annual growth rate (CAGR) of 5.9%[5].

Drivers of Growth

  • Increasing Chronic Diseases: The rising prevalence of chronic diseases is driving the demand for fluid replacement and electrolyte balance solutions.
  • Surgical Procedures: The increasing number of surgeries worldwide contributes to the demand for lactated Ringer's solutions.
  • Healthcare Expenditure: Growth in healthcare expenditure and increasing awareness about fluid management are supporting the market growth.
  • Preference for Standard Formulation: The standard lactated Ringer’s solution segment is expected to contribute the highest market share due to its balanced formulation and widespread acceptance among medical professionals[5].

Market Segments

  • Formulation: The standard lactated Ringer’s solution segment is expected to dominate the market with a 52.1% share in 2024.
  • Volume: The 250 mL segment is expected to contribute the highest share of the market, driven by high demand from outpatient settings[5].

Market Projections

Future Trends

The market for lactated Ringer's solutions, including D5LRS, is expected to witness steady growth driven by several factors:

  • Increasing Demand: Rising demand from both inpatient and outpatient settings will continue to drive the market.
  • Technological Advancements: Improvements in packaging and administration methods, such as compact and convenient packaging, will enhance market growth.
  • Regulatory Support: Continued regulatory approval and guidelines supporting the use of lactated Ringer's solutions will further boost the market[5].

Challenges and Opportunities

  • Competition: The market faces competition from other intravenous fluid solutions, but the balanced formulation and clinical benefits of D5LRS are expected to maintain its market position.
  • Innovation: Opportunities for innovation in formulation and delivery systems could further expand the market share of D5LRS.

Nursing Responsibilities and Administration

Administration Guidelines

  • D5LRS should be administered only if the solution is clear and the container is undamaged.
  • Caution is advised in patients receiving corticosteroids or corticotrophin due to sodium content.
  • Patients with diabetes mellitus should be monitored closely due to the dextrose content.
  • Proper labeling and aseptic technique are essential during administration[1].

Dosage

  • The solution is supplied in single-dose 500 and 1000 mL flexible plastic containers.
  • The typical dosage is 1000 mL at 30 drops per minute or as prescribed by the physician[1].

Key Takeaways

  • Clinical Use: D5LRS is used for fluid replacement, electrolyte balance, and nutritional support.
  • Market Growth: The market is expected to grow with a CAGR of 5.9% from 2024 to 2031.
  • Clinical Trials: Recent trials highlight the benefits of D5LRS over other solutions in terms of serum chloride levels and metabolic acidosis.
  • Nursing Responsibilities: Proper administration and monitoring are crucial to avoid complications.

FAQs

What is the primary use of Dextrose 5% in Lactated Ringer's Solution?

Dextrose 5% in Lactated Ringer's Solution is primarily used for daily maintenance of body fluids, nutrition, and rehydration, as well as for treating shock and providing extra calories to patients who cannot tolerate fluid overload[1].

What are the key components of D5LRS?

The solution contains dextrose, sodium chloride, sodium lactate, potassium chloride, and calcium chloride dihydrate, along with water for injection[2].

What are the potential risks associated with D5LRS administration?

Potential risks include hypersensitivity to any of the components, metabolic alkalosis from excess lactate, and increased serum osmolality in very low birth weight infants. Caution is also advised in patients with diabetes mellitus and those receiving corticosteroids or corticotrophin[1].

How does D5LRS compare to other intravenous fluids in clinical trials?

Recent trials indicate that D5LRS has a lower incidence of hyperchloremic metabolic acidosis compared to 5% Dextrose in Normal Saline, and it maintains better serum chloride levels[4].

What is the projected market size for lactated Ringer's solutions by 2031?

The global lactated Ringer's injection market, including D5LRS, is expected to reach USD 762.2 million by 2031, growing at a CAGR of 5.9% from 2024[5].

What are the main drivers of the growing demand for D5LRS?

The growing demand is driven by the increasing prevalence of chronic diseases, the rising number of surgical procedures, growth in healthcare expenditure, and increasing awareness about fluid management[5].

Sources

  1. RNpedia: D5LRS (Lactated Ringer's Solution) IV Fluid.
  2. DailyMed: DEXTROSE IN LACTATED RINGERS- dextrose, sodium chloride.
  3. PharmaCompass: DEXTROSE 5%; LACTATED RINGER'S IN PLASTIC CONTAINER.
  4. PubMed: 5% Dextrose in Ringer's Lactate versus 5% Dextrose Normal Saline.
  5. Coherent Market Insights: Lactated Ringers Injection Market - Report, Trends, Share & Insights.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.